A key Republican-led congressional committee has taken a significant step to block the federal rescheduling of marijuana, approving a funding bill that contains a provision designed to prevent this reform. This action by the House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies directly defies the Trump administration's recent announcement that it is moving forward with enacting the rescheduling of cannabis.
The approved funding bill includes specific language that, if ultimately enacted into law, would prohibit federal agencies from implementing the Department of Health and Human Services' (HHS) recommendation to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This creates a direct legislative challenge to the executive branch's stated intention to advance cannabis reform.
For dispensary owners, brand managers, and smoke shop buyers, this development introduces a layer of complexity and uncertainty into the federal policy landscape. Rescheduling cannabis from Schedule I to Schedule III would have profound implications, most notably by potentially easing the burdensome 280E tax provision that currently prevents cannabis businesses from deducting ordinary business expenses. It would also likely facilitate increased scientific research and could pave the way for broader federal recognition of cannabis's medical utility.
This committee's vote signals a continued partisan divide on federal cannabis policy, even as public opinion and state-level reforms increasingly favor broader access and legalization. While the Trump administration's initiative reflects a willingness to address federal cannabis laws, this congressional counter-move underscores the fragmented and often contradictory nature of policy-making in Washington D.C. Cannabis businesses should closely monitor the progression of this appropriations bill through Congress, as its final form will dictate whether the path to rescheduling remains clear or faces a legislative roadblock. This event emphasizes the need for strategic planning and adaptability in an ever-evolving regulatory environment.